Organization
University of Arkansas for Medical Sciences (UAMS)
19 abstracts
Abstract
Advancing drug development by leveraging microdissection for proteogenomic analysis of histological sections.Org: University of Arkansas for Medical Sciences (UAMS), Loyola University Maryland, Avoneaux Medical Institute,
Abstract
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus Candida adjuvant alone in treating cervical intraepithelial neoplasia 2/3.Org: University of Arkansas for Medical Sciences (UAMS), Little Rock, AR,
Abstract
Analyzing the characteristics and prognostic outcomes for patients with myelodysplastic syndrome with Q-gene deletion.Org: University of Arkansas for Medical Sciences (UAMS), Highlands Oncology Group, Christina Care Hospital,
Abstract
Association of posterior reversible encephalopathy syndrome with proteasome inhibitors approved for multiple myeloma: Analysis of FAERS database.Org: Rochester General Hospital, Dayanand Medical College, University of Arkansas for Medical Sciences (UAMS),
Abstract
Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.Org: Clínica Universidad de Navarra and CIBEREHD, CIMA, CIBERONC, IDISNA, Myeloma Center,
Abstract
Changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody therapy in patients with relapsed refractory multiple myeloma (RRMM).Org: Medical College of Wisconsin, Milwaukee, Froedtert & Medical College of Wisconsin, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, University of Arkansas Medical Sciences,
Abstract
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols.Org: University of Arkansas for Medical Sciences (UAMS), Jordan University of Science and Technology, University of Arkansas for Medical Sciences Winthrop P. Rockefeller Institute, Myeloma Center, The University of Arkansas for Medical Sciences/Arkansas Children’s Hospital,
Abstract
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).Org: University of Arkansas for Medical Sciences (UAMS),
Abstract
A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blockade in rare tumors (DART) SWOG S1609: The desmoid tumors (cohort 27).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, UC San Diego Moores Cancer Center, University of Kansas Medical Center, Department of Biostatistics & Data Science, Loma Linda University Department of Radiation Technology,
Abstract
Inter-regional differences of authorship in secondary analyses of solid malignancies.Org: University of Jordan, University of Arkansas for Medical Sciences (UAMS),
Abstract
Altmetrics of breast cancer clinical trials’ subgroup analysis: A systematic review.Org: University of Jordan, Amman, Jordan, Jordan University of Science and Technology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR,
Abstract
Use of secondary subgroup analysis of clinical trials across solid malignancies.Org: Medical School of University, the university of Jordan, Amman, Jordan, University of Jordan, University of Arkansas for Medical Sciences (UAMS),
Abstract
Weight loss (WL) as a predictive factor for immune oncology (IO).Org: University of Arkansas for Medical Sciences (UAMS), UAMS Clinical Practice,
Abstract
Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors.Org: MD Anderson Hematology/Oncology Fellowship, MD Anderson Cancer Center, University of Arkansas for Medical Sciences (UAMS), University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy,
Abstract
Safety and feasibility of the addition of a radiosensitizing methionine-restricted diet to radiation therapy.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Rutgers New Jersey Medical School, University of Arkansas for Medical Sciences (UAMS), WVU Health Sciences Ctr,
Abstract
Three years (yrs) maintenance with bortezomib, lenalidomide, and dexamethasone (RVD) in multiple myeloma (MM): Results of Total Therapy (TT) IIIB.Org: University of Arkansas for Medical Sciences (UAMS), Jordan University of Science and Technology, University of Arkansas for Medical Sciences Winthrop P. Rockefeller Institute, Myeloma Center, The University of Arkansas for Medical Sciences/Arkansas Children’s Hospital,
Abstract
Serum IL-6 levels following siltuximab administration in Castleman disease.Org: Perelman School of Medicine at the University of Pennsylvania, University of Pennsylvania, University of Arkansas for Medical Sciences (UAMS), Department of Medicine, Icahn School of Medicine at Mount Sinai, Perelman School of Medicine,
Abstract
Exploring the association between medical marijuana cardholder status and antiemetic overuse.Org: University of Arkansas for Medical Sciences (UAMS), Uniersity of Arkansas for Medical Sciences,
Abstract
Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows.Org: University of Arkansas for Medical Sciences (UAMS), Little Rock, AR,